SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HUTCHMED Highlights SAFFRON Phase III Lung Cancer Trial Results

The company says ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO. Median overall survival increased by nearly five months.

13

Related stories